TL;DR
This review discusses representative astrocyte programs linked to immune modulation, tumor support, and therapy response, including TRAIL-associated, STAT3/CHI3L1-related, and PDGFR-β-associated phenotypes and describes emerging astrocyte-targeted strategies.
Glioblastoma (GBM), a high-grade glioma, is the most common primary brain tumor in adults, with a dismal prognosis and a very high recurrence rate. Major challenges to effective treatment arise from the tumor’s locally aggressive, diffusely infiltrative nature and extensive intratumoral heterogeneity. Recent advances i...
Gliomas, the most common and aggressive primary tumors in the central nervous system, are characterized by high invasiveness and resistance to therapy, making them a major focus of neuro-oncology research. Although substantial progress has been achieved in elucidating their molecular underpinnings in recent years, effe...
This review summarizes the main immunotherapeutic approaches currently investigated, including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and oncolytic viruses, and examines the key biological factors responsible for treatment resistance.
Malignant glioma is a group of primary malignant tumors of the central nervous system with an extremely poor prognosis, with glioblastoma being the most malignant type. Its highly invasive nature, tumor heterogeneity, stubborn immunosuppressive microenvironment, and the barrier effect of the blood-brain barrier result...
It is demonstrated that combined inhibition of MET and mTOR exhibits significant synergy against GBM, and the BNIP3-mTOR axis is identified as a critical mediator of resistance to MET inhibition.
The major obstacles limiting CAR-T therapy in GBM are summarized and emerging strategies to overcome these challenges are discussed, paving the way for future CAR-T-based therapies in glioblastoma.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
